Levi & Korsinsky Informs Pacira BioSciences Shareholders About Class Action Lawsuit and Deadline

Class Action Lawsuit Update: Pacira BioSciences

Levi & Korsinsky, LLP, a well-known law firm specializing in investor rights, is urging shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX) to be aware of a critical upcoming deadline. Investors seeking to be designated as lead plaintiffs in a class action lawsuit related to alleged securities fraud must act before March 14, 2025.

Background of the Lawsuit

This class action focuses on losses incurred by shareholders due to alleged fraudulent activities that may have taken place between August 2, 2023, and August 8, 2024. The complaint, which outlines claims of securities fraud, was prompted by events that culminated in a significant decline of Pacira’s stock price. The precise trigger was a press release issued by Pacira on August 9, 2024, revealing unfavorable legal outcomes concerning its patent claims against eVenus. Importantly, the U.S. Patent No. 11,033,495—the patent covering Pacira’s leading product, Exparel—was deemed invalid, raising concerns about the company's future market positioning and revenue streams.

Following this announcement, Pacira's stock experienced a dramatic fall, plummeting more than 47% from a previous closing price of $22.36 to a low of $11.70 within a single trading day. This sharp decline has led investors to seek legal recourse to recover their losses, thereby prompting Levi & Korsinsky to launch this class action.

Legal Process and Options for Investors

Shareholders who have suffered losses during this specific timeframe have a unique opportunity to step forward and request the court appoint them as lead plaintiffs. However, it is important to note that involvement as a lead plaintiff is not a prerequisite for financial recovery. All class members may benefit from compensation claims without facing upfront financial costs, as the law firm emphasizes that participation incurs no out-of-pocket expenses.

Levi & Korsinsky has built a robust reputation over the past two decades, securing substantial financial settlements for its clients in complex securities litigation. With over 70 team members, the firm has consistently ranked among the top securities litigation firms across the United States.

Next Steps for Concerned Shareholders

For investors interested in pursuing claims against Pacira BioSciences, it is crucial to meet the March 14, 2025, deadline to potentially serve as lead plaintiff. Interested shareholders can reach out to Levi & Korsinsky through multiple channels. Contact Joseph E. Levi at [email protected] or call (212) 363-7500 for guidance and information concerning the lawsuit.

The law firm encourages all affected investors to act promptly, as this case could provide significant restitution for those impacted by the abrupt decline in Pacira's stock value.

For more comprehensive details, investors can find additional information and the submission link for claims at Levi & Korsinsky's official website. Making a claim now allows shareholders to secure their rights while potentially recovering losses sustained during this tumultuous period for Pacira BioSciences.

Contact Information

For inquiries, interested parties can reach out to:

Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Website: www.zlk.com